Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B raises $32.4mm for Catabasis

Executive Summary

Catabasis Pharmaceuticals Inc. (developing therapies for inflammatory, immunological, and metabolic diseases) brought in $32.4mm via a Series B financing to first-time backer Lightstone Ventures, which was joined by an undisclosed public crossover fund and all existing shareholders Advanced Technology Ventures, Clarus Ventures, MedImmune Ventures, and SV Life Sciences. Catabasis says the money should last into 2015 and help the company prep for Phase III trials of its triglyceride-lowering candidate CAT2003 and support ongoing development of other candidates based on its SMART linker conjugate technology.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies